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The ALS-linked E102Q mutation in Sigma receptor-1
leads to ER stress-mediated defects in protein
homeostasis and dysregulation of RNA-binding
proteins
Alice Dreser1, Jan Tilmann Vollrath1, Antonio Sechi2, Sonja Johann3, Andreas Roos1,4,5, Alfred Yamoah1, Istvan Katona1,
Saeed Bohlega6, Dominik Wiemuth7, Yuemin Tian7, Axel Schmidt7, Jörg Vervoorts8, Marc Dohmen8, Cordian Beyer3, Jasper Anink9,
Eleonora Aronica9, Dirk Troost9, Joachim Weis1,10 and Anand Goswami*,1,10
Amyotrophic lateral sclerosis (ALS) is characterized by the selective degeneration of motor neurons (MNs) and their target
muscles. Misfolded proteins which often form intracellular aggregates are a pathological hallmark of ALS. Disruption of the
functional interplay between protein degradation (ubiquitin proteasome system and autophagy) and RNA-binding protein
homeostasis has recently been suggested as an integrated model that merges several ALS-associated proteins into a common
pathophysiological pathway. The E102Q mutation in one such candidate gene, the endoplasmic reticulum (ER) chaperone Sigma
receptor-1 (SigR1), has been reported to cause juvenile ALS. Although loss of SigR1 protein contributes to neurodegeneration in
several ways, the molecular mechanisms underlying E102Q-SigR1-mediated neurodegeneration are still unclear. In the present
study, we showed that the E102Q-SigR1 protein rapidly aggregates and accumulates in the ER and associated compartments in
transfected cells, leading to structural alterations of the ER, nuclear envelope and mitochondria and to subsequent defects in
proteasomal degradation and calcium homeostasis. ER defects and proteotoxic stress generated by E102Q-SigR1 aggregates
further induce autophagy impairment, accumulation of stress granules and cytoplasmic aggregation of the ALS-linked RNA-
binding proteins (RBPs) matrin-3, FUS, and TDP-43. Similar ultrastructural abnormalities as well as altered protein degradation and
misregulated RBP homeostasis were observed in primary lymphoblastoid cells (PLCs) derived from E102Q-SigR1 fALS patients.
Consistent with these findings, lumbar α-MNs of both sALS as well as fALS patients showed cytoplasmic matrin-3 aggregates
which were not co-localized with pTDP-43 aggregates. Taken together, our results support the notion that E102Q-SigR1-mediated
ALS pathogenesis comprises a synergistic mechanism of both toxic gain and loss of function involving a vicious circle of altered
ER function, impaired protein homeostasis and defective RBPs.
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Several familial ALS (fALS) and frontotemporal dementia
(FTD)-linked mutations affect protein homeostasis and autop-
hagy, including ubiquilin-2 (UBQLN2), p62/SQSTM1 (seques-
tosome1), optineurin (OPTN), TANK-binding kinase 1 (TBK1),
valosin-containing protein (VCP), charged multivesicular body
protein 2B (CHMP2B), vesicle-associated membrane protein
B (VAPB) and FIG4.1,2 Recent studies emphasized a
functional interplay between autophagy and RNA processing,
associating several ALS-FTD genes in a converging pathway
leading to insufficient degradation and abnormal aggregation
of proteins.2 Specifically, mutations in RBPs such as Tar DNA-
binding protein-43 (TDP-43), fused in sarcoma (FUS), survival
of motor neuron-1 (SMN1), ataxin-2 (ATX2), optineurin (OPT),
angiogenin (ANG) and matrin-3 (MATR3) cause fALS with
distinct aggregates,3 disturbed autophagy and altered RNA
processing. Even in sporadic ALS (sALS), toxic aggregates of
such proteins in MNs are frequent and can be triggered by
defective UPS/autophagy.4
Aggregation of these RBPs together with other proteins is
physiological and reversible (unfolded protein response,
UPR).5 RBPs control RNA polymerase elongation, mRNA
maturation, transport and degradation, and regulate transcrip-
tional activity and distribution of RNAs by RNA granule
formation. Among the latter, stress granules (SGs) are
generated in response to stressful conditions. Prolonged SG
formation affects protein quality control and vital cellular
processes like apoptosis, signalling and RNA decay.5
Sigma receptor-1 (SigR1) is an ER chaperone involved in
neuronal survival, ion channel activity, Ca2+ signalling, synaptic
plasticity, memory and drug addiction.6 The E102Q-SigR1
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missense mutation causes fALS;7 a splice site mutation (c.151
+1G4T)8 and recently the homozygous E138Q and E150K
mutations9 have been linked to autosomal recessive distal
hereditary motor neuropathy (dHMN). Moreover, SigR1 is
involved in several neurodegenerative disorders including
Parkinson´s, Alzheimer´s and Huntington´s disease.10
We previously described abnormal modification as well as
altered localization of SigR1 protein in sALS patient spinal
cord.11 Mavlyutov et al. demonstrated that lack of SigR1
exacerbates ALS progression in G93A-SOD1 mice.12
SigR1−/− mice showed MND pathology and symptoms.13
In vitro, SigR1 depletion causes Ca2+ dysregulation,
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autophagy defects and ER stress-mediated neuronal
death.11,14 Furthermore, a SigR1 agonist improved motor
function and MN survival in SOD1 mice.15 These studies
suggest a crucial role of SigR1 for neuronal survival. However,
it is still unclear whether E102Q-SigR1 causes ALS due to a
gain or loss of functions.
Using PLCs obtained from E102Q-SigR1 fALS patients7
and autopsy specimens from sALS and fALS patients as
well as cell culture models, we found that E102Q-SigR1
aggregates induce ER stress with distinct ER and nuclear
envelope alterations, impaired Ca2+ homeostasis and autop-
hagy pathways and aberrant extra-nuclear localization of
several ALS-associated RBPs. Our results support the notion
that mutant (m) SigR1 induces neuronal toxicity by a loss of
normal function combined with a toxic gain of abnormal
functions.
Results
mSigR1 aggregation and cellular toxicity. MCF-7 cells
normally express little or no SigR1 (Supplementary Figure 1A).
Over-expressed wtSigR1 showed localization in the ER
(Figures 1d and e), nuclear envelope (Figures 1b and c) and
ER-Golgi intermediate compartment (Figure 1f) of transiently
transfected MCF-7 cells. mSigR1 formed ER-associated
aggregates (Figures 1b and d-f and Supplementary Figures
1B and C) combined with disintegrated ER membranes and
overall cell morphology (Figure 1b,Supplementary Figure 1B).
Shuttling of the nuclear envelope protein Emerin was impaired
(Figure 1c). These results comply with the recently published
crystal structure of SigR1, suggesting that E102Q mutation
favors SigR1 aggregation and toxicity.16 mSigR1 aggregates
did not associate with the Golgi marker GM130, but there was
Golgi dispersal (Figure 1g). SigR1 is abundant at the ER-
mitochondria-associated membrane (MAM).6 Immunoreactiv-
ity for the mitochondrial marker Tim23 was reduced, even
though few enlarged mitochondria (or clusters of mitochondria)
co-localized with SigR1 aggregates (Supplementary
Figure 1H). However, consistent with a recent report,9
mitochondria overall did not associate significantly with these
aggregates, confirmed by mito-red staining (Figures 1h and i).
ERSE reporter assay showed increased ER stress in both
NSC-34 and MCF-7 cells (Figure 1j) expressing mSigR1.
Immunoblotting revealed gel top smear (Figure 1k) and
significantly increased levels of the ER stress markers
GRP78, pEIF2-α, GADD and HSP70 (Figures 1k and l) which
correlated well with the expression level of mSigR1 in a dose-
dependent manner (Supplementary Figures 1D–G). RT-PCR
showed amild, but statistically insignificant increase in RNA of
the ER stress markers ATF4 and ATF6 (Supplementary
Figures 2A–C), whereas E102Q-SigR1 PCLs showed a
significant increase in ATF4, but no ATF6 RNA expression
(Supplementary Figure 2D; see below).
Co-localization of Ubiquitin-positive mSigR1 aggregates
(Figure 1m) with 20S proteasome subunits (Figure 1n)
suggest that they were targeted for UPS-mediated degrada-
tion and interfered with the UPS machinery. Accordingly,
chymotrypsin-like proteasome activity (Figure 1o and
Supplementary Figure 1I) was significantly reduced compared
to cells expressing empty vector (pcDNA) or wtSigR1.
E102Q-SigR1 fALS patients. We generated immortalized
PLCs from blood samples of E102Q-SigR1 fALS patients.7
Interestingly, these cells also showed ER-associated mSigR1
aggregates (Figures 2a–c) which co-localized with accumu-
lated Emerin (Figure 2a). mSigR1 aggregates also co-
localized with several ER stress markers (Figures 2d
and e). Dot blot and immunoblot analysis revealed triton-X
insoluble gel top aggregates and increased levels of GRP78
and pEIF2-α (Figures 2f and g). Elevated levels of ubiquitin
conjugates, HSP70 and GADD further indicated proteotoxic
stress (Figures 2f and g). Accordingly, both PLCs showed
significantly elevated ATF4 mRNA expression (Figure 2h and
Supplementary Figure 2D). mRNAs of other UPR branches
(ATF6, XBP1) remained unchanged (Figure 2h and
Supplementary Figure 2D). Most importantly, SigR1 mRNA
expression showed no significant difference between E102Q-
SigR1 and control PLCs (Figure 2i).
Figure 1 mSigR1 abnormally accumulates in the ER and induces cellular toxicity. (a) Model of the homotrimeric SigR1 (based on ref. 16). Subunits are represented in gray,
secondary structure of one subunit is color-coded; each monomer is composed of an amino-terminal transmembrane domain (red) which crosses the ER membrane from lumen
to cytosol. The transmembrane domain is followed by two α-helices (green) that lead to a β-barrel (light violet), the putative ligand binding domain. Two carboxy-terminal α-helices
(blue) form a hydrophobic membrane-embedded surface. The location of the critical residue Glu-102 (E102Q) is marked by a red dot. Red star and red triangle represent two
recently discovered mutations.9 (b) Reticular pattern of SigR1 staining combined with a distinct nuclear envelope localization (lower panel) in wtSigR1-transfected MCF-7 cells;
globular mSigR1 aggregates (arrows; see also enlargement, middle row) in MCF-7 cells expressing mSigR1. Immunofluorescence; scale bars, 15 μm. (c)
Co-immunofluorescence of wtSigR1 and mSigR1 with emerin as a nuclear envelope marker in MCF-7 cells (arrowheads). Note that the focal emerin accumulations
(arrows) co-localize with SigR1 aggregates. Scale bar, 10 μm. (d and e) Co-localization of wtSigR1 and mSigR1 with the ER markers KDEL and (e) calreticulin in MCF-7 cells.
Scale bar, 15 μm. (f and g) Co-labelling of SigR1 with the β-cop (ER-Golgi-associated compartments) and GM130 (Golgi marker). Note the co-localization of mSigR1 with β-cop
and the Golgi dispersal (arrowheads) in mSigR1 expressing MCF-7 cells. Scale bar, 10 μm. (h) Co-immunofluorescence of wtSigR1 and mSigR1 with mito-red as a marker for
mitochondria in MCF-7 cells. Scale bar, 10 μm. (i) Quantification of the mito-red staining depicted in (h) showing numbers of enlarged mitochondria/random field of view.
(j) NSC34 and MCF-7 cells were co-transfected either with empty pcDNA vector, wtSigR1 or mSigR1 together with the luciferase gene downstream of the ERSE promoter. After
48 h, luciferase units (AU) were analyzed as a measure of ER stress. *Po0.05,**Po0.005, #not significant. (k) MCF-7 cells were transfected with pcDNA, wtSigR1 or mSigR1
as described above and analyzed for ER stress and UPR induction by immunoblotting. (l) Quantification of the band intensities normalized with α-tubulin depicted in k. Values
represent the mean± S.D. of three independent experiments. *Po0.05. (m) Ubiquitin immunoreactivity of wtSigR1 and mSigR1 in MCF-7 cells. Scale bar, 10 μm. (n) Co-
localization of mSigR1 aggregates with the accumulated 20s subunit of the proteasome in MCF-7 cells expressing mSigR1. Scale bar, 10 μm. (o) Chymotrypsin-like proteasomal
activity assays were performed using MCF-7 cells transfected with pcDNA, wtSigR1 and mSigR1, as described in material and methods. Note the significant decrease in
proteasome activity due to mSigR1 expression when compared to wtSigR1 and pcDNA. Means± S.D. of three independent experiments each performed in triplicate. *Po0.05,
**Po0.005, # not significant
Mutant SigR1 in ALS
A Dreser et al
1657
Cell Death and Differentiation
Figure 2 mSigR1 is abnormally accumulated in the ER and induces cellular toxicity in E102Q-SigR1 fALS patient lymphoblastoid cells. (a) Immunoreactivity of globular SigR1
aggregates (arrows) in E102Q-SigR1 fALS patient lymphoblastoid cells compared to the healthy control. Note the co-localization of SigR1 aggregates with the nuclear envelope
marker emerin (arrowhead). Scale bar, 15 μm. (b and c) Co-localization of mSigR1 aggregates with the ER markers KDEL and (c) calreticulin in E102Q-SigR1 fALS patient
lymphoblastoid cells compared to the healthy control. Scale bars, 15 μm. (d and e) Upregulation and co-localization of the ER stress markers GRP78 (d) and pPERK (e) with
mSigR1 aggregates in E102Q-SigR1 fALS patient lymphoblastoid cells compared to the healthy control. Scale bars, 15 μm. (f) Immunoblot analysis of SigR1 and established ER
stress and UPR markers in healthy control and E102Q-SigR1 fALS lymphoblastoid cell lysates. Dot blot analysis (top) shows the presence of triton-X insoluble aggregates in
E102Q-SigR1 fALS lymphoblastoid cells. (g) Quantification of the band intensities normalized with α-tubulin depicted in f. Values represent the mean±S.D. of three independent
experiments. *Po0.05. (h–i) RT-PCR analysis of the UPR pathways in three healthy control lymphoblastoid cell lines compared to two E102Q-SigR1 fALS patient lymphoblastoid
cell lines. E102Q-SigR1 fALS patient’s lymphoblastoid cells showed a significant increase in ATF4 mRNA expression. *Po0.05, # not significant. Note that SigR1 gene
expression does not differ between controls and E102Q-SigR1 fALS patients. (j) E102Q-SigR1 fALS patient’s lymphoblastoid cell (n= 2) and control lymphoblastoid cell (n= 3)
lysates were subjected to chymotrypsin-like proteasomal activity and caspase-3 activity assays as described in material and methods. Values are derived from the average of
three control lymphoblastoid cell lines compared to average of two E102Q-SigR1 fALS patient’s lymphoblastoid cell lines from three independent experiment,**Po0.005.
(k) GM130 and SigR1 immunolabelling in E102Q-SigR1 fALS and control lymphoblastoid cells. Scale bar, 15 μm. (l) Immunoblot analysis using SigR1 antibody to compare
SigR1 levels in lymphoblastoid cells from E102Q-SigR1 patient lymphoblasts and healthy controls as well as transiently transfected MCF-7 cells. Quantification of the band
intensities normalized with α-tubulin is shown below. (#) denotes absence of significant differences
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Decreased proteasomal and increased caspase-3 activity
was consistent with these observations (Figure 2j and
Supplementary Figure 2E). GM130 staining revealed signifi-
cant Golgi dispersal compared to the controls (Figure 2k).
mSigR1 aggregates did not co-localize significantly with
mitochondria (not shown); however, mitochondrial labelling
(JC-1 dye) was significantly reduced (see below, Figure 3h).
Importantly, SigR1 protein levels actually did not differ
significantly between the E102Q-SigR1 PLCs and our
transiently transfected cell lines (Figure 2l); the results
obtained from the E102Q-SigR1 PLCs and the transiently
transfected cell lines were consistent throughout, indicating
that the latter were not due to over-expression artefacts.
mSigR1 impairs overall Ca2+ homeostasis and induces
mitochondrial toxicity. SigR1 is abundant at the MAM and
regulates ER-mitochondria Ca2+ transmission.6 mSigR1
induces mitochondrial toxicity17 and disturbs ER-mitocho-
ndria calcium exchange.9 During ER stress and ER Ca2+-
deprivation, SigR1 translocates to the plasma membrane to
regulate store-operated Ca2+ entry (SOCE) together with
channel proteins like STIM1 and Orai1.18 Expression of
wtSigR1 in our MCF-7 cells efficiently induced IP3R-
mediated Ca2+ release from the ER (Figures 3a and b).
mSigR1, however, failed to trigger efficient Ca2+ release
(Figures 3a and b), confirming a recent report.9 Ionomycin
treatment to activate SOCE (Figure 3c) led to significantly
increased intracellular Ca2+ in cells transfected with wtSigR1,
but not with mSigR1 (Figure 3c). Accordingly, STIM1 protein
levels were significantly reduced in MCF-7 cells expressing
mSigR1 and in E102Q-SigR1 PLCs (Figures 3d and e).
Ca2+ homeostasis and mitochondrial functions are closely
linked. Using the sensitive Tox glow assay we observed
significantly impaired mitochondrial membrane integrity (MI)
and decreased ATP production in mSigR1-transfected cells
(Figure 3f). Consistent with the reduced number of (albeit
enlarged) mitochondria (Figure 1h) and reduced Tim23
immunoreactivity in mSigR1-expressing cells (Supplemen-
tary Figure 1H), the mitochondrial membrane potential was
significantly decreased (disappearance of the red-dotted color
in the JC-1 stain) in both mSigR1-expressing cells (Figure 3g)
and E102Q-SigR1 PLCs (Figure 3h). This led to Cyt-C release
(reduced Cyt-C staining, Figure 3i; arrowheads) in mSigR1-
transfected HeLa and MCF-7 cells.
Structural ER and mitochondria alterations and
accumulation of autophagic material. EM revealed numer-
ous vacuoles in mSigR1-expressing cells (Figure 4a and
Supplementary Figure 3A) many of which were probably
ER-derived and might actually be precursors of autophagic
vacuoles,19 often containing non-degraded autophagic sub-
strates (Figure 4a and Supplementary Figure 3A). There was
prominent ER swelling (Figure 4b, arrows) compared to the
pcDNA control and wtSigR1 over-expressing cells. Higher
magnification revealed several autophagic vacuoles with
characteristic double membranes and sequestered cellular
components in mSigR1-transfected cells (Figure 4c and
Supplementary Figure 3B; arrowheads). Furthermore, expres-
sion of mSigR1 induced ER widening at the MAM
(Supplementary Figure 3C and Figure 4c, arrow) and led to
abnormalities of mitochondrial morphology (swelling of mito-
chondria, mitophagy) (Figure 4d, arrowheads). In contrast,
wtSigR1 over-expressing cells showed rather normal ER,
mitochondria and MAM (Figure 4b and Supplementary
Figure 3C; arrows). Consistent with the nuclear envelope
defects seen previously, expression of mSigR1 induced
prominent outfoldings of the nuclear envelope (Supplem-
entary Figure 3D). EM of E102Q-SigR1 PLCs revealed similar
ultrastructural defects (Figures 4e–h); control PLCs showed
rather normal ER, mitochondria and MAM (Figure 4g).
mSigR1 induces defective autophagy. Autophagy largely
relies on intact ER structure and functions. We showed
morphological ER alterations, disturbed intracellular Ca2+
homeostasis and accumulations of autophagic vacuoles in
both mSigR1-expressing cells and in E102Q-SigR1 PLCs;
thus we hypothesized that mSigR1 might impair autophagic
processes. Autophagy can be monitored at different stages
by several well-established methods.14,20,21
Transfection of mSigR1 in A431 and MCF-7 cells resulted in
increased accumulation of p62 and LC3II (Figure 5a and
Supplementary Figure 4A) together with epidermal growth
factor receptor (EGFR) and LAMP-1 (Figure 5a). Consistent
with the immunoblot results, immunofluorescence (Figure 5b)
and CYTO-ID dye labelling (Figure 5c) showed globular LC3
accumulation co-localized with SigR1 aggregates (arrows) in
mSigR1-transfected cells. Similarly, p62 was accumulated
and abnormally associated with SigR1 aggregates
(Figure 5d). Moreover, in nutrient-starved A431 cells
(to induce autophagy), expression of mSigR1 increased the
stability of p62 and LC3II levels (Supplementary Figure 4B).
Furthermore, autophagy induction (Rapamycin) or inhibition
(Bafilomycin A) only marginally, if at all, affected p62 and LC3II
levels in mSigR1-expressing MCF-7 cells compared to
wtSigR1 controls (Supplementary Figure 4C), suggesting an
impairment of autophagic degradation.
mSigR1 expression in mouse fibroblasts (NIH-3T3) stably
expressing GFP-LC314 led to aggregation and abnormal
accumulation of GFP-LC3 (Figure 5e). Absence of a significant
increase in LC3II and p62 levels even after Bafilomycin-A
treatment also suggested abnormal autophagy (Figure 5f). In
primary MEFs isolated from GFP-LC3 tg mice22 that we
transfected with wtSigR1, normal ER-associated SigR1 stain-
ing and few GFP-LC3 puncta together with very few p62-
positive puncta (Figures 5g and h) were observed. In contrast,
mSigR1-transfected MEFs showed sub-plasmalemmal accu-
mulation of mSigR1 (Figure 5g) together with significant
globular accumulation and co-localization of GFP-LC3 and
p62 (Figure 5h). These findings were corroborated by
immunoblot analyses (Supplementary Figure 4D). Finally
E102Q-SigR1 PLCs showed similar aggregation and co-
localization of p62 and LC3II together with mSigR1 aggregates
(Figure 5i), but no co-localization of LAMP1 and SigR1
aggregates (Supplementary Figure 4F). These findings were
strengthened by Cyto-ID-LC3 labelling yielding large globular
accumulations of LC3 in E102Q-SigR1 PLCs (Figure 5j) and by
p62, LC3 and LAMP1 immunoblots (Figure 5k).
Next, we determined which steps within the autophagic
processing chain (internalization, fusion or lysosomal degra-
dation) were impaired bymSigR1. Over-expression of mSigR1
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in A431 cells did not impair receptor internalization after
10 min of EGF stimulation compared to wtSigR1 (Supplem-
entary Figure 4E). Activated EGFR was efficiently degraded
after internalization in control cells (pcDNA and wtSigR1),
however EGFR in mSigR1-expressing cells were only slightly
reduced (Figure 5l, quantification below). Live cell imaging of a
NIH-3T3 reporter cell line (see Methods and refs 14,23)
showed significant impairment of autophagosomes-lysosome
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fusion in mSigR1-expressing cells as indicated by the minimal
loss of GFP fluorescence and maximal co-localization of RFP
and GFP signals (Figure 5m) compared to controls. Accord-
ingly, EM revealed accumulation of double membrane-bound
autophagosomes (AV) not fusing with lysosomes (Figure 5n).
Altogether, our findings suggest that mSigR1 aggregates
impair the autophagic degradation and clearance of
autophagosomes.
mSigR1 impairs vesicular transport. mSigR1 forms
ER-associated aggregates (Figures 1a and 6a) accompanied
by disturbed ER ultrastructure (Figures 4a and b) and
abnormal Golgi morphology (Figures 1g and 2k). Therefore,
ER/Golgi defects might affect vesicular transport from
ER to Golgi and vice versa. Thus we analyzed VSVG-GFP
fluorescence recovery after photobleaching (FRAP)
imaging.24,25 In control COS-7 cells co-transfected with
VSVG-GFP and either pcDNA or wtSigR1, VSVG-GFP ves-
icle trafficking was efficient as indicated by fast VSVG-GFP
recovery (Figures 6b and c and Supplementary Movie 1). In
contrast, in mSigR1-expressing cells intracellular movement
of VSVG-GFP vesicles was severely impaired (Figures 6b
and c and Supplementary Movie 1). Consistent with this
mSigR1 co-aggregated with the endosomal markers Rab5
and Rab7 (Figure 6d) and early endosomal antigen 1 (EEA1)
was increased together with ER stress and autophagy
markers in immunoblots from mSigR1-transfected COS-7
cells (Figures 6f and g). Recapitulating the known effect of
over-expression of other ER membrane proteins,26 transfec-
tion of wtSigR1 mildly affected EEA1 and LC3II, but not
p62 and GRP78. E102Q-SigR1 PLCs also showed similar
co-aggregation of early (EEA1) and late (Rab7) endosomal
markers with mSigR1 (Figure 6e). Our results are consistent
with a recent study showing reduced intracellular mobility of
mSigR1,27 with previous reports describing that VSVG
transport is impaired by ER stress,24,25 and also with our
own previous work showing ultrastructural abnormalities of
the ER/Golgi complex in SigR1-deficient cells.11,14
mSigR1 accumulation leads to altered distribution of
RBPs. RBPs are multifunctional and play a major role in
sALS pathophysiology.28 Alterations of RBPs homeostasis
can directly or indirectly modulate protein quality control.29
Cytoplasmic aggregates along with granular cytoplasmic
staining for endogenous TDP-43 was found in mSigR1-
transfected MCF-7 cells, but not in controls (Figure 7a).
Similarly cytoplasmic translocation and aggregation of FUS
was observed (Figures 7b and d). MEF-GFP-LC3 cells
expressing mSigR1 showed increased cytoplasmic staining
for endogenous TDP-43 together with increased accumula-
tion of GFP-LC3 (Supplementary Figure 4H).
Mutations in the nuclear matrix protein matrin-3 can cause
fALS30 and autosomal dominant distal myopathy with vocal
cord and pharyngeal weakness;31,32 matrin-3 interacts with
TDP-43, FUS and other RBPs.33 Matrin-3 also showed
cytoplasmic mis-localization in MCF 7 cells expressing
mSigR1 (Figures 7c and d). Occasionally in some cells having
large globular, compact mSigR1 aggregates, matrin-3 was
found exclusively in the cytoplasm with complete loss of
nuclear signal (Figure 7c). Immunoblot analysis of subcellular
fractions of MCF-7 cells confirmed these observations
(Supplementary Figure 4G). Confocal imaging of E102Q-
SigR1 PLCs confirmed that aggregates of mSigR1 were
co-localized with TDP-43 (Figure 7e), FUS (Figure 7f) and
matrin-3 (Figure 7g). Immunoblots of the subcellular fractions
of E102Q-SigR1 PLCs confirmed increased cytoplasmic
matrin-3, TDP43 and FUS (Figure 7h). Consistent with these
findings immunohistochemistry of the lumbar spinal cord of
fALS patients harbouring FUS and C9orf72 mutations
revealed cytoplasmic matrin-3 accumulations in α-MNs
(Figures 7i and j). By double-immunofluorescence these
accumulations did not co-localize with pTDP-43 aggregates
(Supplementary Figures 5A and B) consistent with prior
observations.30 We also confirmed the finding by Johnson
et al.30 that lumbar α-MNs of sALS and fALS patients show
increased nuclear matrin-3 immunoreactivity. Interestingly,
however, in the E102Q-SigR1 transfected cells and in the
E102Q-SigR1 PLCs (Figures 7c and g) a high degree of
cytoplasmic SigR1 accumulation was not only associated with
increased cytoplasmic matrin-3 immunoreactivity, but also
accompanied by a loss of nuclear matrin-3 staining. These
data indicate that cytoplasmic mis-localization of matrin-3 in
sALS and fALS MNs and in E102Q-SigR1 expressing cells
might be pathophysiologically relevant.
Aggregation of these RBPs proceeds through the stress
granule pathway (see above and refs 5,34). Consistent with
Figure 3 mSigR1 induces mitochondrial toxicity and fails to mobilize IP3R and SOCE-mediated Ca2+ signalling. (a and b) MCF-7 cells were transiently transfected as
previously described; 48 h later cells were loaded with Fura-2AM for 30 min, washed twice and then stimulated with 10 μM BDK under Ca2+-free conditions. Average traces of the
BDK-induced increase in [Ca2+]i from the ER store through IP3R are represented. Note the increase of [Ca2+]i in wtSigR1-transfected cells (green curve) compared to a significant
decrease in mSigR1-transfected cells (red curve). Results are expressed as mean± S.E.M. of ~ 30 cells. Mean changes in peak [Ca2+]i measured are given. The asterisks
denote a statistically significant difference (*Po0.05). (c) Representative SOCE elicited in transfected cells loaded with Fura-2AM as described above. SOCE was triggered by
the addition of 2 μM ionomycin under Ca2+-free conditions. SOCE developed (vertical dot line) after the addition of Ca2+ is depicted. (d) STIM1 immunoblot analysis from lysates
obtained from pcDNA, wtSigR1 and mSigR1-transfected MCF-7 cells. Note the significant down-regulation of STIM1 in mSigR1-transfected cells. The fold change below
represents the quantification of band intensities normalized against α-tubulin. Values derived from three independent experiments. *Po0.05. (e) Significantly decreased STIM1
levels in E102Q-SigR1 fALS lymphoblastoid cell lysates compared to healthy control lymphoblastoid cells. The fold change below represents the quantification of band intensities
normalized against α-tubulin. Values derived from three independent experiments. *Po0.05. (f) Significantly reduced mitochondrial membrane integrity and ATP production in
mSigR1 expressing MCF-7 cells compared to wtSigR1 expressing cells measured by the tox glow assay. Values derived from three independent experiments. *Po0.05. (g) JC-1
staining of HeLa cells transfected with wtSigR1 or mSigR1. Note the reduced mitochondrial potential in mSigR1 expressing cells. Scale bar, 10 μm. (h) JC-1 staining of
lymphoblastoid cells obtained from E102Q-SigR1 fALS patients and healthy controls. Note the decreased membrane potential in mSigR1 expressing cells. Scale bar, 10 μm.
(i) Cytochrome C immunolabelling of HeLa and MCF-7 expressing wtSigR1 or mSigR1. Note the Cytochrome C release in cells showing mSigR1 aggregates (arrowheads). Scale
bar, 10 μm
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Figure 4 mSigR1 leads to structural abnormalities of ER and mitochondria. (a) MCF7 cells expressing pcDNA, wtSigR1 or mSigR1 were fixed with 2.5% buffered
glutaraldehyde and processed for EM. Several membrane-bound vacuolar structures (black arrows) probably derived from the ER in a representative mSigR1-expressing cell
compared to cells expressing wtSigR1 and pcDNA control. Scale bars, 1 μm. (b) Higher magnification showing the widened ER (arrows in right panel) in representative mSigR1-
expressing cells compared to pcDNA and wtSigR1-transfected cells. Scale bar, 0.5 μm. (c) Higher magnification showing double membrane autophagic vacuoles in
representative mSigR1-expressing MCF-7 cells. (a) Large autophagosome (AV; arrowheads) containing mitochondria and other structures in close proximity to lysosomes (Lys);
(b) autophagosome (arrowhead) and widened ER (white arrow); (c) autophagosome (AV) and lysosomes (Lys). Scale bar, 0.5 μm. (d) Enlarged mitochondria (arrows) showing
abnormal cristae architecture, some undergoing mitophagy (arrowheads) in mSigR1-transfected cells. Scale bar, 0.4 μm. (e) Primary lymphoblastoid cells from healthy control
and E102Q-SigR1 fALS patients were fixed with 2.5% buffered glutaraldehyde and processed for EM. Control lymphoblasts show an overall normal ultrastructure, whereas
E102Q-SigR1 fALS patient lymphoblastoid cells reveal prominent accumulation of autophagic material. Scale bars, 2.5 μm. (f) Prominent nuclear envelope (arrows) protrusions
in E102Q-SigR1 fALS lymphoblastoid cells and rather normal nuclear envelope in control lymphoblastoid cells. Scale bar, 0.5 μm. (g) Normal ER (white arrows) and mitochondria
(gray arrows) in healthy control lymphoblastoid cells; E102Q-SigR1 fALS patient lymphoblastoid cells showing overall widened ER (arrows). Scale bar, 0.5 μm.
(h) E102Q-SigR1 fALS lymphoblasts displaying vacuolar degeneration of mitochondria (gray arrows), multivesicular bodies (arrowheads) and autophagosomes filled with
membranous and granular material (white arrows). Black arrow: nuclear envelope protrusion. Scale bars, 0.4 μm
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the cytoplasmic mis-localization of several RBPs, MCF-7 cells
expressing mSigR1 showed prominent Tia 1-positive stress
granules co-localized with SigR1 aggregates (Figures 7k and
l) and cytoplasmic P-body formation in both E102Q-SigR1
PLCs and transfected MCF-7 cells (Supplem-
entary Figure 4I and J). However SigR1 aggregates did not
exactly co-localize with adjacent P bodies (Supplem-
entary Figures 4I and J). These results indicate that mSigR1
expression and aggregation leads to abnormal RNA-binding
protein homeostasis and stress granule formation.
E102Q-SigR1 mediated ALS pathogenesis. Schematic
representation (Figure 8) of the interdependent pathophysio-
logical mechanisms of ALS pathogenesis associated with the
E102Q mutation in SigR1.
Discussion
Mutations in several ER proteins, including SigR1, cause
MNDs. For instance, the P56S mutation in the VAPB gene
leads to a form of fALS, ALS-8,35,36 characterized by distinct
ultrastructural ER alterations and defective protein degradation
pathways.37 Similarly, mutations in ER chaperones such as
SIL1, HSPB8 and HSJ1 lead to familial neurodegenerative
disorders including MNDs.38–40 ER (co-) chaperones including
SigR1 and SIL1 accumulate in surviving MNs in sALS and
might serve protective functions.11,41 E102Q-SigR1-associated
disease shows an autosomal recessive inheritance pattern
suggesting a ‘loss-of-function’ pathomechanism consistent with
a recent report42 and also with our previous reports.11,14
However, neither the E102Q nor the recently found homo-
zygous (E138Q and E150K) SigR1mutations9 could be linked
to transcriptional silencing or defective translation so far.
ER stress and structural alterations of the ER/nuclear
envelope. ATF4 is required for the activation of SigR1
transcription and upregulation of SigR1 suppresses ER
stress-mediated cell death, thus considered to be
neuroprotective.43 Consistent with this, Gregianin et al.9
recently showed that over-expression of wtSigR1 suppressed
ER stress-induced mitochondrial injury. We found that
mSigR1 promotes prolonged ER stress (Figures 1j-l and
2d-g) and altered ER/Golgi morphology (Figure 4) followed by
defective endosomal trafficking (Figures 6b and c). We
previously observed ER stress and defects in endosomal
trafficking after SigR1 protein depletion.11,14 Moreover,
E102Q-SigR1 was recently shown to lose its ability to bind
to the MAM, suggesting yet another loss of function
pathomechanism.9 Evidence favoring an additional toxic gain
of function results from very recent findings suggesting
reduced mobility of E102Q-SigR1.27 Analogously, the
wtVAPB protein is involved in UPR and P56S-mutated VAPB
causes ALS-8,35,36 forms ER-associated aggregates, alters
ER/Golgi ultrastructure, protein quality control37,44 and
endosomal trafficking45,46 and causes ER stress-related cell
death in vitro44 and motor abnormalities in P56S-VAPB
transgenic mice.37 Loss of SIL1, another ER (co-)chaperone,
affects ER homeostasis in mouse models;47 loss of a single
functional SIL1 allele in the G93A-SOD ALS mice enhanced
ER stress and exacerbated ALS pathology.41 These results
are reminiscent of the phenotypes in SigR1− /− mice.13
Conversely, AAV delivery of SIL1 to fALS MNs restored ER
homeostasis, delayed muscle denervation and prolonged
survival41 similar to the improved motor function and MN
survival in SOD1 fALS mice after treatment with a SigR1
agonist.15
SigR1 mainly resides at the ER-MAM interface; upon
agonist-mediated activation SigR1 translocates from the ER
to the nuclear envelope where it binds to emerin and recruits
chromatin-remodeling molecules including lamin A/C.48
Knockdown of SigR1 protein induces disruption of the nuclear
envelope complex.48 In line with these observations, we
observed reduced emerin staining of the nuclear envelope in
E102Q-SigR1-transfected cells (Figure 1b) and E102Q-SigR1
PLCs (Figure 2a). In addition, we found aberrant emerin
co-localization with mSigR1 aggregates indicative of an
additional toxic gain of function (Figure 1c,Figure 2a). Inter-
estingly, SIL1-deficient mice and human Marinesco Sjögren
syndrome (MSS) patients lacking SIL1 also display myo-
nuclear envelope defects.47 Consistent with this P56S-VAPB
affects the retrograde trafficking of ERGIC-5349 and shuttling
of emerin from the ER to the inner nuclear membrane,49 and
knockdown of endogenous VAPB actually recapitulates this
phenotype.49 Thus, nuclear envelope defects emerge as a
common denominator of pathologies associated with the ALS
proteins SigR1, VAPB and SIL1.
MAM, mitochondrial impairment and intracellular cal-
cium dysregulation. Deregulation of neuronal intracellular
Ca2+ signaling is a major pathomechanism observed in many
neurodegenerative disorders such as AD, PD, ALS and HD
(reviewed in ref. 50). Besides its chaperone function SigR1
also regulates IP3-mediated Ca2+ homeostasis at the MAM6
and depletion of SigR1 disturbs Ca2+ homeostasis11,14 and
ER-mitochondria crosstalk.13 MAM alterations are involved
not only in ALS but also in AD, PD and in several
axonopathies such as hereditary spastic paraplegia and
axonal Charcot–Marie–Tooth disease (reviewed in ref. 51). In
the present study, mSigR1 expression led to MAM alterations
and impaired SOCE and failed to trigger efficient Ca2+
release from the ER through IP3R (Figures 3a–c). These
calcium handling and MAM defects are most likely caused by
both the observed disruption of ER/mitochondrial structure
and by alterations in STIM1-mediated Ca2+ influx because of
lowered levels of STIM1 in the E102Q-SigR1-expressing
cells (Figures 3d and e). These findings are in line with our
previous studies11,14 and also with the recent study by
Gregianin et al. describing the deleterious effect of two new
mutations in SigR1 (E138Q and E150K) on cell viability due
to an altered MAM and impaired global Ca2+ signalling.9
Interestingly, another study (by Tagashira et al.17) using
transient expression of E102Q-SigR1 showed aberrant
mitochondrial Ca2+ uptake and ATP production,17 consistent
with our results. However, both groups studied only IP3R-
mediated Ca2+ homeostasis and its effects on mitochondria.
In contrast, we also examined STIM1-induced SOCE as an
alternate mechanism causing globally altered Ca2+
homeostasis.
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Proteostasis (UPS/autophagy) and RBPs. The turnover of
TDP-43 and FUS and of other RNA stress granule proteins is
regulated by UPS and autophagy;52,53 chemically augment-
ing autophagic flux leads to the clearance of abnormal
aggregates of these proteins.52,53 Furthermore, alterations
of mRNA biogenesis/processing can modulate protein
expression under various cellular stress responses.29 We
found that mSigR1 aggregation leads to ER stress (Figures 1
and 2), autophagy impairment (Figure 5) and aberrant extra-
nuclear localization and aggregation of the RBPs TDP-43,
FUS and matrin-3 (Figures 7a–h). Matrin-3 regulates
transcription and stability of several RBPs including TDP-43
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and FUS;33 MATR3 mutations cause ALS and distal
myopathy.30–32 Recently, mice over-expressing human
matrin-3 were reported to develop muscular atrophy and
altered spinal cord distribution of matrin-3 protein.54 Con-
sistent with previous reports30–32 on human matrinopathy, we
observed both cytoplasmic and nuclear matrin-3 accumula-
tion in E102Q-SigR1 over-expressing cells, along with the
aggregation of other RBPs relevant to ALS (TDP-43 and
FUS). Furthermore, matrin-3 mis-localization was induced by
misfolded protein stress and impairment of degradation
pathways in mSigR1 expressing cells (Supplementary
Figure 5C). Interestingly, transfected cells showing large
cytoplasmic accumulations of SigR1 also showed increased
cytoplasmic matrin-3 immunoreactivity suggesting that the
E102Q-SigR1 mutation leads to a toxic gain of function
involving matrin-3 (Figures 7c and g). These results are
consistent with a previous report demonstrating cytoplasmic
accumulation of matrin-3 in α-MNs of ALS patients harboring
C9ORF72 and MATR3 mutations. Here, we confirm the
increased cytoplasmic matrin-3 immunoreactivity in
C9ORF72 fALS α-MNs and demonstrate that cytoplasmic
matrin-3 aggregation also occurs in lumbar α-MNs of fALS
patients harboring FUS mutations. Irrespective of the
presence or absence of cytoplasmic matrin-3 aggregation,
we also confirm the observation that nuclear matrin-3 staining
is increased in sALS and fALS lumbar α-MNs.30 However,
unlike mTDP-43 and mFUS, cytoplasmic accumulations of
matrin-3 in fALS α-motor neurons are rare.30 Taken together,
our immunohistochemical data from human ALS autopsy
cases are in line with the above described results obtained
with E102Q-SigR1 over-expressing cultured cells. Our data
indicate that cytoplasmic mis-localization of matrin-3 together
with other RBPs in sALS and fALS cells as well as in E102Q-
SigR1 expressing cells might be pathophysiologically
relevant.
With regard to TDP-43 redistribution in E102Q-SigR1
transfected cells, our data confirm results of a recent study17
describing TDP-43 mis-localization along with deranged
mitochondrial ATP production and proteasome activity as a
consequence of mSigR1 over-expression. Our observations
are also in accordance with studies examining a causal
relationship of other ER proteins like Sil1 and VAPB with
TDP-43 proteinopathy. P56S-VAPB, for instance, potentiated
the TDP-43-induced MN death, whereas wt-VAPB had
opposite effects.45
We observed that both the ER stressor thapsigargin and the
autophagy inhibitor bafilomycin A led to similar extra-nuclear
localization of TDP-43 and matrin-3 in NSC-34 (motor neuron-
like) cells; induction of autophagy either by rapamycin or by the
SigR1 agonist PRE084 prevented this mis-localization
(Supplementary Figures 5C and D). SigR1 agonists such as
PRE084 have already been shown to reduce protein
aggregation and ER stress11 and to be neuroprotective.15
Thus, our data suggest that the ALS proteins SigR1, TDP-43
and matrin-3 are interdependent in regulating cellular protein
quality control pathways and that dysregulation of the RBPs
matrin-3, FUS and TDP-43 can be directly caused by mSigR1
aggregation. In addition, indirect mechanisms such as
autophagy impairment due to mSigR1 expression could be
active, supporting a simultaneous toxic gain and loss of
function of mSigR1 (summarized in Figure 8), similar to the
recently described pathomechanism (s) related to mutated
TDP-43, C9orf72, FUS,46 SOD1 (ref. 55) and VAPB.44,49
Materials and Methods
Reagents. Fluorescent nucleic acid stain Hoechst 33258 was purchased from
Molecular Probes (Eugene, OR, USA). Thapsigargin,Tunicamycin, EGF, Rapamycin,
Bafilomycin A, Fura 2AM, NaCl, KCl, pluronic acid, CaCl2, MgCl2, glucose, HEPES
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid, N-acetyl-Asp-Glu-Val-Asp-7
amido-4-methylcoumarin and Bradykinin were purchased from Sigma Aldrich
(Munich, Germany). Suc-Leu-Leu-Val-Tyr-AMC was received from Enzo (Lausen,
Switzerland). Alamar Blue was purchased from Invitrogen, Thermo Fischer
Scientific, Carlsbad, CA, USA. The CYTO-ID Autophagy detection kit was
purchased from Enzo.
Antibodies. The antibodies used in this study and their dilutions are described
in Supplementary Table 1.
Cell culture, transient transfection and treatments
Cell culture and treatment: Human epithelial cancer cells (HeLa), African
green monkey kidney cells (COS-7), human breast cancer cells (MCF-7) and
NSC34 motor neuron-like cells were cultured in Dulbecco's modified Eagle's
Figure 5 mSigR1 leads to defective autophagy and autophagosome-lysosome fusion. (a) Immunoblot analysis for autophagy markers in A431 cells transiently transfected
with pcDNA, wtSigR1 and mSigR1. Note the increased levels of autophagy markers in mSigR1 expressing cells. (b–d) MCF-7 cells were transiently transfected with wtSigR1 or
mSigR1 and then processed for (b) co-immunolabelling using SigR1 and LC3 antibodies, (c) co-immunolabelling using SigR1 and Cyto-ID dye (for labelling autophagosomes)
and (d) co-immunolabelling using SigR1 and p62 antibodies. Scale, 10 μm. (e) Increased accumulation of autophagosomes in the stable autophagy reporter cell line NIH3T3-
GFP transfected with mSigR1. Green: GFP-LC3; red: SigR1; scale bar, 10 μm. (f) Immunoblot analysis of NIH3T3-GFP-LC3 cells transfected with wtSigR1 or mSigR1 and
additionally treated with the autophagy inhibitor Bafilomycin A for 2 h. Note the unchanged LC3-II levels in mSigR1-transfected cells after Bafilomycin A treatment. Corresponding
densitometric data are shown at the bottom; where the upper number represents the relative LC3II/Tub levels and the lower numbers are the S.D. The asterisks (*) denote
significant differences (*Po0.05), while # denotes absence of a significant difference. (g and h) Primary fibroblasts isolated from autophagy reporter GFP-LC3 transgenic mice
were transfected with wtSigR1 or mSigR1 and immuno-labelled by SigR1 (g) and p62 (h) antibody (merge image for GFP-LC3, green, and SigR1/p62, red). Note the localization
of SigR1 at the periphery of this particular cell (g, arrowheads) and the co-localization of GFP-LC3 with globular p62 accumulations. Scale bar, 10 μm. (i) Co-localization of SigR1
with p62 and LC3 in E102Q-SigR1 fALS lymphoblastoid cells compared to healthy control lymphoblastoid cells. (j) Cyto-ID (green) staining (right) showing the accumulation of
autophagosomes in E102Q-SigR1 fALS lymphoblastoid cells. (k) Immunoblot analysis of established autophagy markers in E102Q-SigR1 fALS lymphoblastoid cells in
comparison to healthy controls. (l) A431 cells were transfected as described above. Forty-eight hours later, transfected cells were processed for the EGFR degradation assay as
described in Materials and Methods and analyzed by immunoblotting with the EGFR antibody. Note the delayed EGFR degradation in mSigR1 expressing cells. (lower)
Quantification of immunoblot analysis. Values are expressed as mean± S.D. from three independent experiments. *Po0.05. (m) NIH3T3 cells expressing RFP-GFP-LC3 were
transfected with pcDNA, wtSigR1 or mSigR1. Forty-eight hours later the fusion of autophagosomes with lysosomes was measured by live cell imaging. Scale bar, 25 μm. (lower)
The rate of autophagosomematuration reflected by the Pearson coefficient (green/red fluorescence ratio) at each time point indicated. Values are represented as means± S.E.M.
of triplicate experiments *Poo0.0001. (n) EM picture of NIH-3T3 cells stably expressing RFP-GFP-LC3 transfected with mSigR1. Note the autophagosome (white arrow) and
lysosomes (gray arrow) without any fusion
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Figure 6 mSigR1 impairs ER to Golgi transport. (a) Cos7 cells showing abnormal SigR1 accumulations (arrows) after mSigR1 transfection and normal ER localization of
SigR1 (right) after wtSigR1 transfection. Scale bar, 15 μm. (b) Cos7 cells were co-transfected with VSVG-GFP together with pcDNA, wtSigR1 or mSigR1. 48 h after transfection,
fluorescence associated with the Golgi complex was photobleached (FRAP, see Materials and Methods) with a high-intensity laser beam. Subsequently, the inward delivery of
VSVG-GFP from pre-Golgi intermediates was monitored for the indicated periods of time. Scale bar, 10 μm. (c) Fluorescence recoveries after photobleaching curves of mSigR1-
transfected cells show a clear decrease of the mobile fraction as compared to cell transfected with pcDNA or wtSigR1. Error bars indicate the S.E.M.; (right) the comparison of the
mobile fractions in pcDNA, wtSigR1 and mSigR1 expressing cells. In the box plots, the line in the middle of the box indicates the median; the top line indicates the 75th quartile,
whereas the bottom line indicates the 25th quartile. Whiskers represent the 10th and 90th (upper) percentile, respectively. (d) mSigR1 aggregates (arrowheads) co-localize with
the endosomal markers Rab5 (upper) and Rab7 (lower) in Cos-7 cells transfected with wtSigR1 and mSigR1, respectively. Scale bar, 10 μm. (e) Co-localization of mSigR1
aggregates with the endosomal markers EEA1 and Rab7 in E102Q-SigR1 fALS patients´ lymphoblastoid cells compared to healthy controls. Scale bars, 15 μm. (f) Immunoblot
analysis of Cos-7 cells transfected with pcDNA, wtSigR1 and mSigR1. (g) Quantification of band intensities normalized against α-tubulin depicted in (f). Values are expressed as
mean± S.D. from three independent experiments. *Po0.05
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medium (DMEM, Invitrogen), supplemented with 10% FBS and 1% antibiotic/anti-
mycotic solution (Invitrogen). Mouse embryonic fibroblasts (MEF) obtained from the
GFP-LC3 transgenic mice22 were also maintained in DMEM supplemented with
10% FBS and 1% antibiotic/anti-mycotic solution. The human epidermoid carcinoma
cell line A431 was grown in Dulbecco's modified Eagle's medium (DMEM,
Invitrogen) supplemented with 10% FBS and 0.1% Gentamycin. NIH-3T3 cells
stably expressing GFP-LC3 or tandem mCherry-EGFP-LC3 were cultured in DMEM
supplemented with 10% FBS, 1% penicillin/streptomycin and puromycin (Sigma
Aldrich). Lymphoblasts obtained from E102Q-SigR1 fALS patients and healthy
controls were cultured in RPMI 1640 medium containing 20% FBS, 1% penicillin/
streptomycin, 1% L-glutamin and 0.056% amphotericin. Cells were maintained in a
humidified incubator at 37 °C and 5% CO2. Generation of NIH-3T3 cells stably
expressing GFP-LC3 or tandem mCherry-EGFP-LC3 with retroviral infection is
described elsewhere.14
Plasmids and transfection. In order to investigate the molecular
mechanisms of E102Q-SigR1-related pathogenesis, cells were transfected to
express either wtSigR1 or mSigR1. The vectors for the ectopic expression of
wtSigR1 or E102Q-SigR1 have been described already.7 The empty pcDNA vector
was used as a transfection control. All cell lines were transfected using
Lipofectamine 2000 reagent (Invitrogen) according to the manufacturer’s
recommendations. After 4h incubation at 37 °C and 5% CO2 the transfection
reagent containing medium was replaced by fresh medium and analysis was
performed 48h later. VSVG-GFP used for vesicle transport analysis was a kind gift
of Prof. Jennifer Lippincott-Schwartz. For proteasome activity analysis, cells were
co-transfected with either pcDNA, wtSigR1 or mSigR1.
Post-mortem tissues and Immunohistochemistry. Paraffin sections
of human post-mortem lumbar spinal cord (n= 6 age-matched controls, n= 15
sALS, n= 9 C9orf72, n= 4 FUS; ALS patients) were obtained from the
Amsterdam Academic Medical Center (AMC), Division of neuropathology,
Department of Pathology ALS Bank (Amsterdam, The Netherlands) Research
Code provided by the Medical Ethics Committee of the AMC (Amsterdam, The
Netherlands; approved protocol: W11_073). The post-mortem tissues were obtained
within 6–12 h after death. All tissues were used in compliance with the Declaration
of Helsinki.
Immunohistochemistry was performed as previously described56 on paraffin
sections (5–6 μm thickness), de-waxed, rehydrated and heated in Citrate Buffer
(pH 6.0), (Thermo Scientific concentrate cat.no.- 005000) for antigen retrieval.
Sections were then incubated with primary antibody (Supplementary Table 1) for 1 h
at room temperature. After washing in 0.1M PBS, sections were incubated with
appropriate HRP-conjugated secondary antibodies (1:200, Immunologic, Duiven, The
Netherlands) for 1 h, followed by 3,3-diaminobenzidine (DAB) visualization
(Immunologic). For double immunofluorescence, secondary antibodies conjugated
with Alexa fluor 594 and Alexa-fluor 488 were used (Invitrogen), followed by cover
slipping with mounting medium containing diamidinophenylindole (DAPI) for nuclear
counterstain. Immunoperoxidase stained sections were visualized and photographed
using a Zeiss Axioplan microscope with a Zeiss Axiocam HR camera (Zeiss,
Oberkochen, Germany) and immunofluorescence was visualized using a Zeiss LSM
700 confocal microscope (Zeiss) and images processed using Zeiss LSM software
and Adobe Photoshop CS5.
Immunocytochemistry. HeLa, MCF-7, Cos-7, MEF and NIH-3T3 cells were
cultured on μ-dishes (ibidi, GmbH, Planegg/Martinsried, Germany) and transiently
transfected either with wtSigR1 or mSigR1. After 48 h cells were fixed in 4% PFA
and processed for confocal microscopy. Permeabilization with 0.5% Triton X100 and
blocking with 4% skimmed milk/goat serum was followed by primary antibody
incubation overnight at 4 °C. Secondary Alexa488- or Alexa594-conjugated anti-
mouse or anti-rabbit antibodies (Invitrogen) were used for visualization. Nuclei were
stained with Hoechst 33342 (1 μg/ml) or were mounted with DAPI containing
fluorescent mounting media (DAKO) and visualized using a Zeiss LSM 700 confocal
microscope. Resulting images were processed using the Zeiss LSM software and
Adobe Photoshop CS5 (Adobe Systems, San Jose, CA, USA).
Fura-2 calcium imaging. The intracellular calcium ion concentration, [Ca2+]i,
was measured using a conventional Fura-2 technique as previously described.11
After 48 h of transfection with pcDNA, wtSigR1 or mSigR1, NSC-34 and MCF-7
cells cultured in glass bottom μ-dishes (ibidi), were loaded with the membrane-
permeable AM-form of Fura-2 (1.5 ng/μl; Invitrogen) in the presence of pluronic acid
(25 %) for 30 min at 37 °C. Emitted fluorescence at 530 nm (detected using a PCO
(Sensicam: pco.imaging), Kelheim, Germany) in response to alternate excitation at
340 nm and 380 nm (using the Polychrome V monochromator; TILL Photonics,
Gräfelfing, Germany) was used to measure intracellular Ca2+ concentrations. Data
were shown as emission ratios in response to 340 nm /380 nm excitation. Whole-
cell calcium measurements of NSC-34 and MCF-7 cells transfected with pcDNA,
wtSigR1 or mSigR1 were obtained at room temperature (23–25 °C). During the
imaging procedure, cells were kept in a bathing solution containing 100 mM NaCl,
5.4 mM KCl, 2 mM CaCl2, 1 mM MgCl2, 10 mM HEPES, 10 MES, 5.5 glucose and
pH was adjusted to 7.4.
ER stress assay. To investigate the ER stress levels in pcDNA, wtSigR1 and
mSigR1 expressing cells, we used the ERSE reporter system (Cignal reporter
assay kit, Qiagen Cat. No.–CCS-2032L, Hilden, Germany) in combination with the
dual luciferase system (Promega Cat.No. – E1910, Madison, WI, USA) according to
the manufacturers´ protocols. Cells were co-transfected with pcDNA, wtSigR1 and
mSigR1 together with the ERSE reporter construct containing the luciferase gene.
After 24 h of incubation, luciferase activity was measured by using the dual
luciferase assay for firefly and renilla luciferase detection.
Mitochondrial toxicity assay. Mitochondrial toxicity exerted by mSigR1 was
measured using the mitochondrial ToxGlo assay kit (Promega: Cat. No–G8000)
according to the manufacturer´s protocol. MCF-7 cells were plated on a 96 well
plate and transfected with wtSigR1 or mSigR1. 48 h after transfection, cells were
incubated with cytotoxicity reagent at 37 °C for 30 min and fluorescence was
measured at 520 nm.This value represents the membrane integrity (MI). Thereafter
the same plate was equilibrated at room temperature and then incubated with the
ATP detection substrate; luminescence was measured after 5 min–1 h for the
detection of ATP production.
Transmission electron microscopy (TEM). MCF-7 and NSC-34 cells
were transfected with pcDNA, wtSigR1 or mSigR1 as described above. Cells were
collected by scraping, suspended lymphoblast cultures from healthy controls and
ALS patients were collected by brief centrifugation (5000 r.p.m. for 5 min) and then
washed in 0.1 M phosphate buffer and immediately fixed with 2.5% glutaraldehyde
in 0.1 M phosphate buffer for 24 h followed by washing in buffer for another 24 h.
Cell pellets were collected by centrifugation (1000 r.p.m., 5 min) and embedded in
2% agarose (at 60 °C; Fluka #05073). Small blocks of embedded cells were sliced
and post-fixed in 2.5% glutaraldehyde for 24 h followed by washing in 0.1 M
phosphate buffer for 24 h. Agarose blocks were then incubated in 1% OsO4 (in
0.2 M phosphate buffer) for 3 h, washed twice in distilled water and dehydrated with
using ascending alcohol concentrations (i.e., 25, 35, 50, 70, 85, 95 and 100%; each
step for 5 min). Dehydrated blocks were incubated in propylenoxide followed by
subsequent 20 min incubation in a 1:1 mixture of epon (47.5% glycidether, 26.5%
dodenylsuccinic acid anhydride, 24.5% methylnadic anhydride and 1.5% Tris
(dimethylaminomethyl) phenol) and propylenoxide. The samples were then
incubated in epoxy resin for 1 h at room temperature followed by polymerization
(28 °C for 8 h, 80 °C for 2.5 h and finally at room temperature for 4 h). Ultra-thin
sections (70 nm) were mounted on grids for electron microscopy and examined
using a Philips CM10 transmission electron microscope (Philips, Amsterdam,
The Netherlands) as already described.11
Fluorescence recovery after photobleaching (FRAP). For live cell
imaging experiments, Cos7 cells were seeded on glass-bottomed dishes (ø 6 cm)
and co-transfected either with pcDNA/VSVGts045-GFP, wtSigR1/VSVGts045-GFP
or mSigR1/ VSVGts045-GFP. VSVGts045-GFP was allowed to accumulate in the
ER at 42 °C for 8 h and cells were imaged on an Axio Observer Z1 inverted
microscope equipped with heating stage and CO2 controller (Zeiss) maintained at a
constant temperature of 32 °C. A portion of the ER (ø ~ 3.84μm) in the periphery of
the cell was photobleached using a 405 nm laser driven by the UGA-40 control unit
(Rapp Opto Electronic GmbH, Wedel, Germany). The recovery of the fluorescent
signal was monitored by imaging the cells every second for 15 min. Imaging was
done using an Evolve EM-CCD camera driven by ZEN software (Zeiss). For all
experiments the bleached area and the duration of the laser impulse were kept
constant. The extent of recovery of the fluorescent signal was determined using
ImageJ to measure the average pixel intensity values within three distinct regions of
interest: ROI1: bleached area, ROI2: unbleached area within the cell and ROI3:
background. Normalized FRAP recovery curves and the mobile fraction were
calculated using the program easy FRAP.
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Live cell imaging to analyze RFP-GFP-LC3 fusion. To analyze the
dynamics of the RFP-GFP-LC3 fusion protein, GFP and RFP channels were
acquired every minute for up to 4 h using the imaging system described above. The
extent of autophagosome maturation was determined by measuring the
co-localization of the GFP and RFP signals as expressed by the Pearson’s
coefficient using ZEN software.
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Immunoblot analysis. Cells were washed twice with ice-cold PBS and
scraped off the culture plate. After centrifugation at 6000 r.p.m. for 5 min and
removal of the supernatant, cell pellets were re-suspended in lysis buffer
(0.5% Triton X-100 in PBS, 0.5 mM PMSF and complete protease inhibitor mixture,
Roche Applied Sciences, Mannheim, Germany) and incubated on ice for 30 min
followed by a sonification with an amplitude of 8% for 10 s. Clear lysates were
obtained after centrifugation for 5 min at 6000 r.p.m. Protein concentrations were
determined using the BCA method (Molecular Probes). Equal amounts of protein
were boiled for 5 min in 2 × SDS sample buffer and subjected to 10 or 12% SDS–
PAGE electrophoresis at 80 mA before transferred to a polyvinylidenedifluoride
membrane, which had to be activated in methanol before. Transfer lasts 1 h and
30 min at 350 mA and was followed by blocking in 4% skimmed milk in 0.05%
Tween 20/Tris-buffered saline (TBS-T) for 30 min before incubation with primary
antibody. The dilutions for primary antibodies are described in Supplementary Table
1. After incubating the primary antibody overnight at 4 °C under gently shaking,
membranes were washed three times with TBS-T for 10 min each and incubated
with the appropriate horseradish peroxidase-conjugated secondary antibody for 1 h
(antibody dilution 1:10 000) followed by the same washing procedure. Mutant SigR1
aggregates were detected by using dot blot analyis. For this, lymphoblastoid cell
lysates were directly brought on a nitrocellulose membrane and after applying a
vacuum, membranes were processed following our established western blot
protocol. Immunoreactive proteins were detected by enhanced chemiluminescence
(Amersham Biosciences, Mannheim, Germany). Densitometric quantification of the
band intensity was normalized to tubulin levels using Adobe Photoshop CS5.
EGFR endocytosis, starvation and degradation assay. For EGFR
endocytosis and degradation analysis, A431 cells were starved in DMEM without
serum for 4 h. After starvation, cells were treated with EGF (100 mg) to stimulate
EGFR endocytosis. Cells were then collected at various time points (as indicated in
Figures 3l and m) and lysed in RIPA buffer (50 mM Tris–HClpH 7.5, 1% Triton
X-100, 150 mM NaCl, 1 mM EDTA and 0.1% Na deoxycholate) containing protease
inhibitor. Protein extracts were resolved by SDS–PAGE and immunoblotted using
anti-EGFR antibody.
EGFR surface biotinylation assay. Surface biotinylation assays were
performed as previously described14 with minor modifications. Briefly, transfected
A431 cells were starved in DMEM without serum for 4 h. After starvation, cells were
treated with EGF to stimulate EGFR endocytosis and then preceded for surface
biotinylation assay according to the manufacturer´s protocol.
Mito-red staining. MCF-7 cells were grown on coverslips and transfected with
wtSigR1 or mSigR1. After 48 h cells were incubated with the mito-red dye for
10 min at 37 °C and processed according to the manufacturer´s protocol for
adherent cells. For quantification of enlarged mitochondria mito-red stained cells
were visualized with the LSM 700 confocal microscope using the 40 × lens.
Enlarged mitochondria (showing accumulation of mito-red staining and larger in size
than normal mitochondria) from 10 random fields and at least capturing 8–10 cells
per field of view were counted manually.
CYTO-ID Autophagy detection. MCF-7 cells were grown on coverslips and
transfected with wtSigR1 or mSigR1. After 48h cells were incubated with the
CYTO-ID dye (Enzo, Lausen, Switzerland) for 30 min at 37 °C and processed
according to the manufacturer´s protocol for adherent cells. Lymphoblastoid cells
derived from E102Q-SigR1 fALS patients and healthy controls were processed
following the manufacturer´s instructions for suspension cells. Both were analyzed
by confocal microscopy.
Enzyme activity assays and cell viability. NSC-34 cells were
transfected with pcDNA, wtSigR1 or mSigR1 as described previously. After 48h
incubation, cells were washed twice with ice-cold PBS and scraped off the culture
plate using a cell scraper. Cell pellets were lysed in homogenization buffer for
15 min (10 mM Tris-HCl (ph 7.4), 1 mM EDTA, 5 mM DTT, 5 mM ATP, 20% glycerol
and complete protease inhibitor mixture, Roche Applied Sciences) and processed
for the proteasome activity assay (Jana). Proteasome activity was measured by
using the proteasome substrate Suc-Leu-Leu-Val-Tyr-AMC. Lymphoblasts obtained
from patients or healthy control individuals were processed for the caspase-3
activity assay following the same protocol using the caspase-3 substrate N-Acetyl-
Asp-Glu-Val-Asp-7 amido-4-methylcoumarin.
Cell viability (mitochondrial activity) was determined by using Alamar Blue.
Therefore, NSC34 cells were grown in 24 well plates and transfected according to the
protocol described before. Alamar Blue was added to the medium in a 1:10 dilution
and absorbance was measured after 2 h at 570 nm.
Cellular fractionation. The subcellular distributions of distinct proteins were
determined by using a subcellular fractionation kit following the manufacturer´s
protocol (Thermo Scientific/Life Technologies) and analyzed by immunoblotting. The
Figure 8 Illustration showing the proposed mechanisms of ALS pathogenesis
associated with the E102Q mutation in SigR1
Figure 7 mSigR1 accumulation leads to altered RNA-binding protein homeostasis. (a) Co-staining of SigR1 and TDP-43 in MCF-7 cells transfected with either wtSigR1 or
mSigR1. Note the minor cytoplasmic TDP-43 accumulations (white arrow) without co-localization with SigR1, in contrast to the more pronounced TDP-43 aggregates co-
localizing with SigR1 in E102Q-SigR1 fALS lymphoblastoid cell depicted in e. Scale bar, 15 μm. (b) Translocation of FUS from the nucleus (yellow arrow) to the cytoplasm (white
arrow) and co-localization with SigR1 aggregates in MCF-7 cells expressing mSigR1 compared to wtSigR1-transfected cells. Scale bar, 10 μm. (c) Immunofluorescence staining
of SigR1 and matrin-3 in MCF-7 cells expressing wtSigR1 or mSigR1. Note the cytoplasmic accumulations (white arrow) along with the loss of nuclear matrin-3 (yellow arrow)
corresponding to the higher amount of globular mSigR1 aggregates. Scale bar, 10 μm. (d) Quantification (n= 3 each) of the experiments illustrated in (a–c). *Po0.05. (e–g)
Nuclear loss of TDP43 (e), FUS (f) and matrin-3 (g) and their co-localization with mSigR1 aggregates in E102Q-SigR1 fALS lymphoblastoid cells compared to healthy controls.
Scale bar, 10 μm. (h) Immunoblot analysis of subcellular fractions obtained from E102Q-SigR1 patients´ lymphoblastoid cell lines compared to healthy controls (n= 2 for fALS;
n= 3 for control). Matrin-3, FUS and TDP-43 distributions are shown in the cytoplasmic (Cyto.), membrane (Memb.) and nuclear (Nucl.) fractions. Note the translocation of matrin-
3 from the nucleus to the cytoplasm in E102Q-SigR1 patients´ lymphoblastoid cells. Tubulin is used as a loading control and Lamin A as a positive control for the nuclear fraction.
(i) Immunohistochemical analysis of lumbar α-MNs using matrin-3 antibody in sALS and fALS compared to normal controls. Cytoplasmic accumulation (arrowheads, middle) of
matrin-3 in α-MNs of fALS patients harbouring FUS and C9ORF72 mutations. Strong nuclear immunoreactivity of matrin-3 (arrows) is evident in sALS α-MNs (right), whereas the
control shows an overall weaker nuclear matrin-3 signal (arrows, left). Paraffin sections, DAB-immunohistochemistry; scale bars, 20 μm. (j) Quantification of
immunohistochemical data illustrated in I; for the immunohistochemical analysis n= 12 sALS; n= 8 (C9ORF72); n= 4 (FUS) and n= 4 control cases were examined. *Po0.05,
while # denotes absence of significance (k) loss of nuclear Tia1 (yellow arrows) and accumulation of cytoplasmic Tia-1 (white arrow in the middle panel) positive stress granules
co-localized with mSigR1 aggregates in MCF-7 cells. Scale bar, 15 μm. (l) Quantification of data shown in (k). *Po0.05
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subcellular fractionation was performed with patients´ and control lymphoblasts as
well as with NSC34 cells transfected according to the described procedure.
Statistical analysis. We used the unpaired Student’s t-test for comparison
between two sample groups. Values were expressed as mean±S.D. from three
independent experiments. For Ca2+ measurements results were expressed as
means± S.E.M. of ~ 30 cells. For the FRAP and co-localization experiments, we
used the Mann–Whitney U-test. For both statistical tests, differences between the
compared experimental conditions were regarded as significant when *Po0.05,
**Po0.005.
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